What is the increased risk of breast cancer associated with the Mirena intrauterine system (levonorgestrel-releasing intrauterine device)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Increased Breast Cancer Risk with Mirena IUD

The Mirena (levonorgestrel-releasing intrauterine system) is associated with a modest increased risk of breast cancer, with the most recent and highest-quality evidence showing approximately a 38% increased risk (HR 1.38), particularly elevated during the first 3 years of use.

Current Evidence on Breast Cancer Risk

The most recent large-scale study from 2025 1 provides the strongest evidence on this question. This Korean national database study of over 61,000 women found:

  • Overall increased risk: Hazard ratio of 1.38 (95% CI 1.19-1.59)
  • Incidence rates: 223 cases per 100,000 person-years in LNG-IUS users vs. 154 per 100,000 in non-users
  • Time-dependent pattern: Risk is highest in early years and appears to decrease over time:
    • First 3 years (early): HR 5.40 (95% CI 4.04-7.22) - dramatically elevated
    • First 3 years (late): HR 1.04 (95% CI 0.55-2.00) - returns to baseline
    • 3-5 years: HR 3.44 early, declining to 1.75 late
    • 5+ years: HR 1.77 (95% CI 1.26-2.48)

Conflicting Evidence and Context

The evidence base shows significant heterogeneity:

Studies showing increased risk:

  • A 2020 meta-analysis 2 found increased risk across all age groups (OR 1.16 overall, 1.52 in women ≥50 years)
  • A 2016 Finnish cohort study 3 demonstrated elevated risk for both ductal (SIR 1.20) and lobular (SIR 1.33) breast cancer, with highest risk in repeat users (SIR 1.73 for lobular cancer)

Studies showing no increased risk:

  • Two meta-analyses from 2021 4 and 2023 5 found no significant association
  • These analyses included different study populations and methodologies, potentially explaining the discrepancy

Clinical Guidelines Framework

The U.S. Medical Eligibility Criteria (2010) 6 classifies LNG-IUD use by breast cancer status:

  • Current breast cancer: Category 4 (unacceptable health risk - do not use)
  • Past breast cancer (>5 years disease-free): Category 3 (risks usually outweigh benefits)
  • Undiagnosed breast mass: Category 2 (benefits generally outweigh risks)
  • Family history or benign disease: Category 1 (no restrictions)

The guidelines note that "breast cancer is a hormonally sensitive tumor" and acknowledge theoretical concerns about disease progression with LNG-IUD use 6.

Clinical Implications and Risk Stratification

High-risk scenarios requiring caution:

  • Women with personal history of breast cancer (contraindicated if current disease)
  • Strong family history or genetic predisposition (BRCA carriers)
  • Age ≥50 years (higher relative risk in this group)
  • Planned long-term use (>5 years)

The early peak in risk (first 3 years) 1 suggests either:

  1. Detection bias (increased surveillance after device insertion)
  2. Promotion of existing subclinical disease
  3. True hormonal effect on breast tissue

Important caveats:

  • The absolute risk increase remains relatively small given the low baseline breast cancer incidence in reproductive-age women (72 per 100,000 in women aged 20-49) 7
  • Methodological limitations exist across studies, including confounding by indication (women using LNG-IUS for menorrhagia may have different baseline risks)
  • The protective effects against endometrial cancer are well-established and substantial 8

Risk-Benefit Counseling

When prescribing Mirena, explicitly discuss:

  • The approximately 38% relative increase in breast cancer risk based on the most recent evidence
  • The particularly elevated risk during the first 3 years of use
  • Individual baseline risk factors (age, family history, breast density)
  • The proven benefits for heavy menstrual bleeding and endometrial protection
  • Alternative contraceptive options (copper IUD has no hormonal effects and no breast cancer association)

Consider alternative contraception in:

  • Women with current or recent (<5 years) breast cancer
  • Strong family history with multiple affected first-degree relatives
  • Known BRCA1/2 mutations (though evidence here is mixed 9)
  • Women who express significant concern about breast cancer risk

The evidence has evolved substantially, with the 2025 Korean study 1 providing the most robust and recent data suggesting a real, though modest, increased risk that clinicians should acknowledge when counseling patients about Mirena use.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.